The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland
- 27 April 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 15 (4) , 667-673
Abstract
(2015). The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland. Expert Review of Pharmacoeconomics & Outcomes Research: Vol. 15, No. 4, pp. 667-673.Keywords
This publication has 8 references indexed in Scilit:
- How to Estimate Productivity Costs in Economic EvaluationsPharmacoEconomics, 2014
- Systemic Lupus Erythematosus - Disease Impact on PatientsCentral European Journal of Public Health, 2013
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010
- The Euro-lupus project: epidemiology of systemic lupus erythematosus in EuropeLupus, 2009
- The cost of systemic sclerosisArthritis Care & Research, 2008
- SarcoidosisOrphanet Journal of Rare Diseases, 2007
- Systemic sclerosisBest Practice & Research Clinical Rheumatology, 2002
- Indirect costs of disease; an international comparisonHealth Policy, 1995